See a real life example of how PTMScan technology can facilitate translational discovery. In this short video we describe how CST not only identified a major driver of NSCLC, which can respond to an FDA approved drug, but went a step further and developed an antibody that can be used to test which patients might be candidates for treatment. All thanks to the power of simplified proteomics.
Whether your lab is well-versed and equipped to do Mass Spec analysis in-house or your lab has never considered setting up a proteomics experiment before, the Proteomics group at CST has a solution to help clear the way. Click below to watch the video and learn more.
Post Translational Modification: Antibody Enrichment for Mass Spectrometry-based Proteomics
Continuing our theme of simplifying proteomics we present a webinar featuring Matthew Stokes, Ph.D., principal scientist of the proteomics group here at Cell Signaling Technology and Christopher Rose, Ph.D., a postdoctoral research fellow in the Gygi Lab at Harvard Medical School.
Dr. Stokes describes PTMScan® technology, a method that uses antibodies to enrich specific post-translationally modified (PTM) peptides (e.g., phosphorylated, methylated, ubiquitinated etc) from a complex mixture prior to LC-MS/MS analysis. Dr. Rose demonstrates how, by combining PTMScan technology with isobaric labeling, specifically with tandem mass tags (TMTs), his lab quantified over 15,000 ubiquitination events in Bortezomib treated cells.